ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptive Biotechnologies Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$23.95−0.07 (-0.29%)
Close on Oct 19, 2026
- Market cap
- $3.83B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$7.65 (+46.93%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Adaptive Biotechnologies Corp grew revenue 50.1% to $308.08M over the twelve months to Jun 30, 2026. Free cash flow was -$24.03M.
Revenue
$308.08M
+50.1% vs. a year earlier
Operating income
-$37.46M
TTM Q2 2026
Free cash flow
-$24.03M
TTM Q2 2026
EPS, diluted
-$0.41
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.83B
- P/E ratio
- –
- Price to sales
- 12.43
- Price to book
- 26.79
- Dividend yield
- –
- Free cash flow yield
- -0.63%
Fundamentals
- Revenue
- $308.08M
- Net income
- -$63.85M
- EPS, diluted
- -$0.41
- Free cash flow
- -$24.03M
- Book value per share
- $0.89
- Diluted shares
- 160M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$308.08M+50.1% YoY
Gross profit
$232.83M+71.8% YoY
Operating income
-$37.46M
Net income
-$63.85M
EPS, diluted
-$0.41
Free cash flow
-$24.03M
Reported periodTrailing twelve months